Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 720987, 11 pages
http://dx.doi.org/10.1155/2014/720987
Research Article

Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF-κB Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis

1Division of Cardiology, Department of Internal Medicine, Foundation for Medical Researches, University of Geneva, 64 Avenue de la Roseraie, 1211 Geneva, Switzerland
2Department of Internal Medicine, University of Genoa, 6 Viale Benedetto XV, 16132 Genoa, Italy
3First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 16132 Genoa, Italy
4Vascular and Endovascular Surgery Unit, Department of Surgery, San Martino Hospital, 10 Largo Rosanna Benzi, 16132 Genoa, Italy
5Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland

Received 12 September 2013; Accepted 22 December 2013; Published 6 February 2014

Academic Editor: Massimiliano M. Corsi Romanelli

Copyright © 2014 Sébastien Lenglet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Yeboah, J. J. Carr, J. G. Terry et al., “Computed tomography-derived cardiovascular risk markers, incident cardiovascular events, and all-cause mortality in nondiabetics: the multi-ethnic study of atherosclerosis,” European Journal of Preventive Cardiology. In press.
  2. D. M. Hermann, J. Gronewold, N. Lehmann et al., “Coronary artery calcification is an independent stroke predictor in the general population,” Stroke, vol. 44, pp. 1008–1013, 2013. View at Publisher · View at Google Scholar
  3. W. E. Shaalan, H. Cheng, B. Gewertz et al., “Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation,” Journal of Vascular Surgery, vol. 40, no. 2, pp. 262–269, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Naghavi, P. Libby, E. Falk et al., “From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I,” Circulation, vol. 108, no. 14, pp. 1664–1672, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Naghavi, P. Libby, E. Falk et al., “From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II,” Circulation, vol. 108, no. 15, pp. 1772–1778, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. E. M. Gravallese, “Osteopontin: a bridge between bone and the immune system,” Journal of Clinical Investigation, vol. 112, no. 2, pp. 147–149, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Schoppet, K. T. Preissner, and L. C. Hofbauer, “RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 4, pp. 549–553, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. S. A. Steitz, M. Y. Speer, M. D. McKee et al., “Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification,” The American Journal of Pathology, vol. 161, no. 6, pp. 2035–2046, 2002. View at Google Scholar · View at Scopus
  9. A. Quercioli, F. Mach, M. Bertolotto et al., “Receptor activator of NF-κB ligand (RANKL) increases the release ofneutrophil products associated with coronary vulnerability,” Thrombosis and Haemostasis, vol. 107, no. 1, pp. 124–139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. D. H. Henry, L. Costa, F. Goldwasser et al., “Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma,” Journal of Clinical Oncology, vol. 29, no. 9, pp. 1125–1132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Lipton, K. Fizazi, A. T. Stopeck et al., “Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials,” European Journal of Cancer, vol. 48, no. 16, pp. 3082–3092, 2012. View at Publisher · View at Google Scholar
  12. Z. Reiner, A. L. Catapano, G. De Backer et al., “ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS),” European Heart Journal, vol. 32, no. 14, pp. 1769–1818, 2011. View at Publisher · View at Google Scholar
  13. F. Akdim, S. I. van Leuven, J. J. P. Kastelein, and E. S. G. Stroes, “Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?” Current Pharmaceutical Design, vol. 13, no. 10, pp. 1003–1012, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. B. G. Brown, X.-Q. Zhao, D. E. Sacco, and J. J. Albers, “Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease,” Circulation, vol. 87, no. 6, pp. 1781–1791, 1993. View at Google Scholar · View at Scopus
  15. P. M. Ridker, E. Danielson, F. A. H. Fonseca et al., “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein,” The New England Journal of Medicine, vol. 359, no. 21, pp. 2195–2207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Crisby, G. Nordin-Fredriksson, P. K. Shah, J. Yano, J. Zhu, and J. Nilsson, “Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization,” Circulation, vol. 103, no. 7, pp. 926–933, 2001. View at Google Scholar · View at Scopus
  17. F. Montecucco, V. Di Marzo, R. F. Da Silva et al., “The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques,” European Heart Journal, vol. 33, no. 7, pp. 846–856, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Montecucco, N. Vuilleumier, S. Pagano et al., “Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability,” European Heart Journal, vol. 32, no. 4, pp. 412–421, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Naci, J. J. Brugts, R. Fleurence, and A. E. Ades, “Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials,” European Journal of Preventive Cardiology, vol. 20, no. 4, pp. 658–670, 2013. View at Publisher · View at Google Scholar
  20. F. Montecucco, S. Lenglet, A. Gayet-Ageron et al., “Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke,” Stroke, vol. 41, no. 7, pp. 1394–1404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. C. R. Dhore, J. P. M. Cleutjens, E. Lutgens et al., “Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 12, pp. 1998–2003, 2001. View at Google Scholar · View at Scopus
  22. P. P. Dimitrow, M. Jawień, and A. Gackowski, “The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis,” The Journal of Heart Valve Disease, vol. 20, no. 1, pp. 18–22, 2011. View at Google Scholar · View at Scopus
  23. W. S. Browner, L.-Y. Lui, and S. R. Cummings, “Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 631–637, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Jono, Y. Ikari, A. Shioi et al., “Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease,” Circulation, vol. 106, no. 10, pp. 1192–1194, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Schoppet, A. M. Sattler, J. R. Schaefer, M. Herzum, B. Maisch, and L. Hofbauer, “Increased osteoprotegerin serum levels in men with coronary artery disease,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 3, pp. 1024–1028, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Bucay, I. Sarosi, C. R. Dunstan et al., “Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification,” Genes and Development, vol. 12, no. 9, pp. 1260–1268, 1998. View at Google Scholar · View at Scopus
  27. B. A. N. Verhoeven, F. L. Moll, J. A. F. Koekkoek et al., “Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy,” Stroke, vol. 37, no. 8, pp. 2054–2060, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Tian, X. Gu, Y. Sun et al., “Effect of statin therapy on the progression of coronary atherosclerosis,” BMC Cardiovascular Disorders, vol. 12, article 70, 2012. View at Publisher · View at Google Scholar
  29. C. P. Cannon, B. A. Steinberg, S. A. Murphy, J. L. Mega, and E. Braunwald, “Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy,” Journal of the American College of Cardiology, vol. 48, no. 3, pp. 438–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. J. Tikkanen, M. Szarek, R. Fayyad et al., “Total cardiovascular disease burden: comparing intensive with moderate statin therapy: insights from the IDEAL (Incremental Decrease in End Points through Aggressive Lipid Lowering) trial,” Journal of the American College of Cardiology, vol. 54, no. 25, pp. 2353–2357, 2009. View at Publisher · View at Google Scholar · View at Scopus